Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Assets (2016 - 2025)

Historic Assets for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $82.7 billion.

  • Gsk's Assets rose 971.34% to $82.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 billion, marking a year-over-year increase of 971.34%. This contributed to the annual value of $76.0 billion for FY2024, which is 356.76% up from last year.
  • Per Gsk's latest filing, its Assets stood at $82.7 billion for Q3 2025, which was up 971.34% from $79.1 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Assets ranged from a high of $112.1 billion in Q2 2022 and a low of $60.4 billion during Q1 2022
  • Its 5-year average for Assets is $83.1 billion, with a median of $76.3 billion in 2024.
  • As far as peak fluctuations go, Gsk's Assets plummeted by 4388.74% in 2022, and later surged by 1789.42% in 2023.
  • Gsk's Assets (Quarter) stood at $106.6 billion in 2021, then tumbled by 33.84% to $70.5 billion in 2022, then increased by 3.81% to $73.2 billion in 2023, then rose by 4.21% to $76.3 billion in 2024, then increased by 8.42% to $82.7 billion in 2025.
  • Its Assets was $82.7 billion in Q3 2025, compared to $79.1 billion in Q2 2025 and $76.5 billion in Q1 2025.